SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.v71.3 http://doi.org/10.3322/caac.v71.3 https://onlinelibrary.wiley.com/toc/15424863/71/3 https://onlinelibrary.wiley.com/toc/15424863/71/3

SIEGEL R L , MILLER K D , JEMAL A . Cancer statistics, 2015 [J ] . CA A Cancer J Clin , 2015 , 65 ( 1 ): 5 - 29 . DOI: 10.3322/caac.21254 http://doi.org/10.3322/caac.21254 http://doi.wiley.com/10.3322/caac.21254 http://doi.wiley.com/10.3322/caac.21254

CHEN W Q , ZHENG R S , BAADE P D , et al . Cancer statistics in China, 2015 [J ] . CA A Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 . DOI: 10.3322/caac.21338 http://doi.org/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338

XIA C F , DONG X S , LI H , et al . Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J ] . Chin Med J (Engl) , 2022 , 135 ( 5 ): 584 - 590 .

LOTAN Y , RAMAN J D , KONETY B , et al . Urinary analysis of FGFR 3 and TERT gene mutations enhances performance of cxbladder tests and improves patient risk stratification [J ] . J Urol , 2022 , 209 ( 4 ): 762 - 772 . DOI: 10.1097/JU.0000000000003126 http://doi.org/10.1097/JU.0000000000003126 http://www.auajournals.org/doi/10.1097/JU.0000000000003126 http://www.auajournals.org/doi/10.1097/JU.0000000000003126

ZHANG B F , JIA P L , WANG J Y , et al . Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer [J ] . Mol Oncol , 2022 . [Online ahead of print ]

MERTENS L S , CLAPS F , MAYR R , et al . Prognostic markers in invasive bladder cancer: FGFR 3 mutation status versus P53 and Ki-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients [J ] . Urol Oncol , 2022 , 40 ( 3 ): 110.e1 - 110.e9 . DOI: 10.1016/j.urolonc.2021.10.010 http://doi.org/10.1016/j.urolonc.2021.10.010 https://linkinghub.elsevier.com/retrieve/pii/S1078143921004750 https://linkinghub.elsevier.com/retrieve/pii/S1078143921004750

LIU Z P , ZENG H , JIN K F , et al . TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer [J ] . Br J Cancer , 2022 , 126 ( 9 ): 1310 - 1317 . DOI: 10.1038/s41416-022-01703-y http://doi.org/10.1038/s41416-022-01703-y

SHI M J , FONTUGNE J , MORENO-VEGA A , et al . FGFR 3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias [J ] . Eur Urol , 2023 , 83 ( 1 ): 70 - 81 . DOI: 10.1016/j.eururo.2022.09.030 http://doi.org/10.1016/j.eururo.2022.09.030 https://linkinghub.elsevier.com/retrieve/pii/S0302283822027075 https://linkinghub.elsevier.com/retrieve/pii/S0302283822027075

XIA Y , WANG X , LIU Y , et al . PKM2 is essential for bladder cancer growth and maintenance [J ] . Cancer Res , 2022 , 82 ( 4 ): 571 - 585 .

GALLO D , YOUNG J T F , FOURTOUNIS J , et al . CCNE 1 amplification is synthetic lethal with PKMYT1 kinase inhibition [J ] . Nature , 2022 , 604 ( 7907 ): 749 - 756 . DOI: 10.1038/s41586-022-04638-9 http://doi.org/10.1038/s41586-022-04638-9

FU S Q , YAO S Y , YUAN Y , et al . Multicenter phase Ⅱ trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification [J ] . J Clin Oncol , 2022 . [Online ahead of print ]

ZHANG C , YANG T . Long non-coding RNA LINC00473 promotes breast cancer progression via miR-424-5p/CCNE1 pathway [J ] . Protein Pept Lett , 2023 , 30 ( 1 ): 72 - 84 . DOI: 10.2174/0929866530666221026164454 http://doi.org/10.2174/0929866530666221026164454 https://www.eurekaselect.com/210396/article https://www.eurekaselect.com/210396/article

YAO S Y , MERIC-BERNSTAM F , HONG D , et al . Clinical characteristics and outcomes of phase Ⅰ cancer patients with CCNE1 amplification: MD Anderson experiences [J ] . Sci Rep , 2022 , 12 ( 1 ): 8701 . DOI: 10.1038/s41598-022-12669-5 http://doi.org/10.1038/s41598-022-12669-5

BELLMUNT J , KIM J , REARDON B , et al . Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer [J ] . Cancer Res , 2020 , 80 ( 20 ): 4476 - 4486 . DOI: 10.1158/0008-5472.CAN-20-0977 http://doi.org/10.1158/0008-5472.CAN-20-0977

DENEKA A Y , BACA Y , SEREBRIISKII I G , et al . Association of TP 53 and CDKN 2 A mutation profile with tumor mutation burden in head and neck cancer [J ] . Clin Cancer Res , 2022 , 28 ( 9 ): 1925 - 1937 . DOI: 10.1158/1078-0432.CCR-21-4316 http://doi.org/10.1158/1078-0432.CCR-21-4316 https://aacrjournals.org/clincancerres/article/28/9/1925/694450/Association-of-TP53-and-CDKN2A-Mutation-Profile https://aacrjournals.org/clincancerres/article/28/9/1925/694450/Association-of-TP53-and-CDKN2A-Mutation-Profile

HARTMANN A , MOSER K , KRIEGMAIR M , et al . Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma [J ] . Am J Pathol , 1999 , 154 ( 3 ): 721 - 727 .

BARTOLETTI R , CAI T , NESI G , et al . Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer [J ] . J Surg Res , 2007 , 143 ( 2 ): 422 - 427 .

TRYBEK T , KOWALIK A , GÓŹDŹ S , et al . Telomeres and telomerase in oncogenesis [J ] . Oncol Lett , 2020 , 20 ( 2 ): 1015 - 1027 . DOI: 10.3892/ol.2020.11659 http://doi.org/10.3892/ol.2020.11659

VERMA S , SHANKAR E , LIN S , et al . Identification of key genes associated with progression and prognosis of bladder cancer through integrated bioinformatics analysis [J ] . Cancers (Basel) , 2021 , 13 ( 23 ): 5931 . DOI: 10.3390/cancers13235931 http://doi.org/10.3390/cancers13235931 https://www.mdpi.com/2072-6694/13/23/5931 https://www.mdpi.com/2072-6694/13/23/5931

XU Y J , ZENG H , JIN K F , et al . Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer [J ] . J Immunother Cancer , 2022 , 10 ( 3 ): e003416.

MA Z K , LI X D , MAO Y Z , et al . Interferon-dependent SLC14A1 + cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer [J ] . Cancer Cell , 2022 , 40 ( 12 ): 1550 - 1565 . e7. DOI: 10.1016/j.ccell.2022.11.005 http://doi.org/10.1016/j.ccell.2022.11.005 https://linkinghub.elsevier.com/retrieve/pii/S1535610822005529 https://linkinghub.elsevier.com/retrieve/pii/S1535610822005529

ZHANG Z , LIANG Z J , LI D , et al . Development of a CAFs-related gene signature to predict survival and drug response in bladder cancer [J ] . Hum Cell , 2022 , 35 ( 2 ): 649 - 664 . DOI: 10.1007/s13577-022-00673-w http://doi.org/10.1007/s13577-022-00673-w

LIU L L , HOU Y X , DENG C Q , et al . Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment [J ] . Nat Commun , 2022 , 13 ( 1 ): 6740 . DOI: 10.1038/s41467-022-34495-z http://doi.org/10.1038/s41467-022-34495-z

LIU Y D , ZHANG Q M , XING B C , et al . Immune phenotypic linkage between colorectal cancer and liver metastasis [J ] . Cancer Cell , 2022 , 40 ( 4 ): 424 - 437 . e5. DOI: 10.1016/j.ccell.2022.02.013 http://doi.org/10.1016/j.ccell.2022.02.013

JI Q , ZHOU L H , SUI H , et al . Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation [J ] . Nat Commun , 2020 , 11 ( 1 ): 1211 . DOI: 10.1038/s41467-020-14869-x http://doi.org/10.1038/s41467-020-14869-x

DU T C , ZHANG K , ZHANG Z B , et al . ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway [J ] . Revista Brasileira De Pesquisas Med E Biol , 2022 , 55 : e11989.

PETERSON C M , HELTERBRAND M R , HARTGERINK J D . Covalent capture of a collagen mimetic peptide with an integrin-binding motif [J ] . Biomacromolecules , 2022 , 23 ( 6 ): 2396 - 2403 . DOI: 10.1021/acs.biomac.2c00155 http://doi.org/10.1021/acs.biomac.2c00155 https://pubs.acs.org/doi/10.1021/acs.biomac.2c00155 https://pubs.acs.org/doi/10.1021/acs.biomac.2c00155

HAAG S L , SCHIELE N R , BERNARDS M T . Enhancement and mechanisms of MC3T3-E1 osteoblast-like cell adhesion to albumin through calcium exposure [J ] . Biotechnol Appl Biochem , 2022 , 69 ( 2 ): 492 - 502 . DOI: 10.1002/bab.v69.2 http://doi.org/10.1002/bab.v69.2 https://onlinelibrary.wiley.com/toc/14708744/69/2 https://onlinelibrary.wiley.com/toc/14708744/69/2

LAFORGUE L , FERTIN A , USSON Y , et al . Efficient deformation mechanisms enable invasive cancer cells to migrate faster in 3D collagen networks [J ] . Sci Rep , 2022 , 12 ( 1 ): 7867 . DOI: 10.1038/s41598-022-11581-2 http://doi.org/10.1038/s41598-022-11581-2

DU G F , PATZELT S , VAN BEEK N , et al . Mucous membrane pemphigoid [J ] . Autoimmun Rev , 2022 , 21 ( 4 ): 103036.

ZHENG R , DU M L , GE Y Q , et al . Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing [J ] . Oncogene , 2021 , 40 ( 13 ): 2382 - 2394 . DOI: 10.1038/s41388-021-01672-1 http://doi.org/10.1038/s41388-021-01672-1

WALTER V , DEGRAFF D J , YAMASHITA H . Characterization of laminin-332 gene expression in molecular subtypes of human bladder cancer [J ] . Am J Clin Exp Urol , 2022 , 10 ( 5 ): 311 - 319 .

PICHLER R , TULCHINER G , FRITZ J , et al . Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study [J ] . Int J Med Sci , 2017 , 14 ( 9 ): 811 - 819 . DOI: 10.7150/ijms.19929 http://doi.org/10.7150/ijms.19929

HENTSCHEL A E , BEIJERT I J , BOSSCHIETER J , et al . Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation [J ] . Clin Epigenetics , 2022 , 14 ( 1 ): 19 . DOI: 10.1186/s13148-022-01240-8 http://doi.org/10.1186/s13148-022-01240-8

OSSOLIŃSKI K , RUMAN T , COPIÉ V , et al . Metabolomic and elemental profiling of blood serum in bladder cancer [J ] . J Pharm Anal , 2022 , 12 ( 6 ): 889 - 900 . DOI: 10.1016/j.jpha.2022.08.004 http://doi.org/10.1016/j.jpha.2022.08.004

SONG P , WU L R , YAN Y H , et al . Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics [J ] . Nat Biomed Eng , 2022 , 6 ( 3 ): 232 - 245 . DOI: 10.1038/s41551-021-00837-3 http://doi.org/10.1038/s41551-021-00837-3

XIAO Y , JU L G , QIAN K Y , et al . Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study [J ] . Clin Transl Med , 2022 , 12 ( 8 ): e1008.

WITJES J A , BRUINS H M , CATHOMAS R , et al . European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines [J ] . Eur Urol , 2021 , 79 ( 1 ): 82 - 104 . DOI: 10.1016/j.eururo.2020.03.055 http://doi.org/10.1016/j.eururo.2020.03.055

PARK J C , CITRIN D E , AGARWAL P K , et al . Multimodal management of muscle-invasive bladder cancer [J ] . Curr Probl Cancer , 2014 , 38 ( 3 ): 80 - 108 . DOI: 10.1016/j.currproblcancer.2014.06.001 http://doi.org/10.1016/j.currproblcancer.2014.06.001 https://linkinghub.elsevier.com/retrieve/pii/S0147027214000403 https://linkinghub.elsevier.com/retrieve/pii/S0147027214000403

KOBAYASHI K , MATSUMOTO H , MISUMI T , et al . The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase Ⅱ study [J ] . Jpn J Clin Oncol , 2022 , 52 ( 10 ): 1201 - 1207 .

QIU J L , ZHANG H F , XU D K , et al . Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis [J ] . J Oncol , 2022 , 2022 : 7306198.

ALATI A , FABIANO E , GEISS R , et al . Bladder preservation in older adults with muscle-invasive bladder cancer: a retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule [J ] . J Geriatr Oncol , 2022 , 13 ( 7 ): 978 - 986 . DOI: 10.1016/j.jgo.2022.05.014 http://doi.org/10.1016/j.jgo.2022.05.014

MARCQ G , SOUHAMI L , CURY F L , et al . Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer [J ] . Int J Radiat Oncol Biol Phys , 2021 , 110 ( 3 ): 738 - 741 . DOI: 10.1016/j.ijrobp.2020.12.033 http://doi.org/10.1016/j.ijrobp.2020.12.033 https://linkinghub.elsevier.com/retrieve/pii/S0360301620347295 https://linkinghub.elsevier.com/retrieve/pii/S0360301620347295

FUKUSHIMA H , YOSHIDA S , KIJIMA T , et al . Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti-PD-1 treatment efficacy in urothelial carcinoma [J ] . Int J Mol Sci , 2021 , 22 ( 2 ): 535 . DOI: 10.3390/ijms22020535 http://doi.org/10.3390/ijms22020535 https://www.mdpi.com/1422-0067/22/2/535 https://www.mdpi.com/1422-0067/22/2/535

ALMARZOUQ A , KOOL R , AL BULUSHI Y , et al . Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer [J ] . Urol Oncol , 2022 , 40 ( 5 ): 194.e15 - 194.e22 . DOI: 10.1016/j.urolonc.2021.11.002 http://doi.org/10.1016/j.urolonc.2021.11.002 https://linkinghub.elsevier.com/retrieve/pii/S1078143921004828 https://linkinghub.elsevier.com/retrieve/pii/S1078143921004828

PATIL G , BASU A . Emerging perioperative therapeutic approaches in muscle invasive bladder cancer [J ] . Ther Adv Urol , 2022 , 14 : 17562872221134389.

Advanced Bladder Cancer ABC Meta-analysis Collaborators Group . Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials [J ] . Eur Urol , 2022 , 81 ( 1 ): 50 - 61 . DOI: 10.1016/j.eururo.2021.09.028 http://doi.org/10.1016/j.eururo.2021.09.028 https://linkinghub.elsevier.com/retrieve/pii/S0302283821020583 https://linkinghub.elsevier.com/retrieve/pii/S0302283821020583

MIRON B , HOFFMAN-CENSITS J H , ANARI F , et al . Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer [J ] . Eur Urol Oncol , 2020 , 3 ( 4 ): 544 - 547 . DOI: S2588-9311(20)30028-6 http://doi.org/S2588-9311(20)30028-6

GROENENDIJK F H , DE JONG J , FRANSEN VAN DE PUTTE E E , et al . ERBB 2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy [J ] . Eur Urol , 2016 , 69 ( 3 ): 384 - 388 . DOI: 10.1016/j.eururo.2015.01.014 http://doi.org/10.1016/j.eururo.2015.01.014

LI Q , DAMISH A W , FRAZIER Z , et al . ERCC 2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer [J ] . Clin Cancer Res , 2019 , 25 ( 3 ): 977 - 988 . DOI: 10.1158/1078-0432.CCR-18-1001 http://doi.org/10.1158/1078-0432.CCR-18-1001

GIL-JIMENEZ A , VAN DORP J , CONTRERAS-SANZ A , et al . Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer [J ] . Eur Urol , 2023 , 83 ( 4 ): 313 - 317 . DOI: 10.1016/j.eururo.2022.07.023 http://doi.org/10.1016/j.eururo.2022.07.023 https://linkinghub.elsevier.com/retrieve/pii/S0302283822025386 https://linkinghub.elsevier.com/retrieve/pii/S0302283822025386

WANG M L , CHEN X L , TAN P , et al . Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer [J ] . Cancer Cell , 2022 , 40 ( 9 ): 1044 - 1059 .e8. DOI: 10.1016/j.ccell.2022.08.010 http://doi.org/10.1016/j.ccell.2022.08.010

PFISTER C , GRAVIS G , FLÉCHON A , et al . Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial [J ] . J Clin Oncol , 2022 , 40 ( 18 ): 2013 - 2022 .

HALL E , HUSSAIN S A , PORTA N , et al . Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial [J ] . Eur Urol , 2022 , 82 ( 3 ): 273 - 279 . DOI: 10.1016/j.eururo.2022.04.017 http://doi.org/10.1016/j.eururo.2022.04.017

BASILE G , BANDINI M , GIBB E A , et al . Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial [J ] . Clin Cancer Res , 2022 , 28 ( 23 ): 5107 - 5114 . DOI: 10.1158/1078-0432.CCR-22-2158 http://doi.org/10.1158/1078-0432.CCR-22-2158

SYLVESTER R J , BRAUSI M A , KIRKELS W J , et al . Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder [J ] . Eur Urol , 2010 , 57 ( 5 ): 766 - 773 . DOI: 10.1016/j.eururo.2009.12.024 http://doi.org/10.1016/j.eururo.2009.12.024

SALOMÉ B , SFAKIANOS J P , RANTI D , et al . NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer [J ] . Cancer Cell , 2022 , 40 ( 9 ): 1027 - 1043 .e9. DOI: 10.1016/j.ccell.2022.08.005 http://doi.org/10.1016/j.ccell.2022.08.005

YOU S , KIM M , HOI X P , et al . Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy [J ] . J Natl Cancer Inst , 2022 , 114 ( 10 ): 1380 - 1391 . DOI: 10.1093/jnci/djac140 http://doi.org/10.1093/jnci/djac140

FUNT S A , LATTANZI M , WHITING K , et al . Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase Ⅱ trial [J ] . J Clin Oncol , 2022 , 40 ( 12 ): 1312 - 1322 . DOI: 10.1200/JCO.21.01485 http://doi.org/10.1200/JCO.21.01485 https://ascopubs.org/doi/10.1200/JCO.21.01485 https://ascopubs.org/doi/10.1200/JCO.21.01485

SZABADOS B , KOCKX M , ASSAF Z J , et al . Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder [J ] . Eur Urol , 2022 , 82 ( 2 ): 212 - 222 . DOI: 10.1016/j.eururo.2022.04.013 http://doi.org/10.1016/j.eururo.2022.04.013

ROSENBERG J , SRIDHAR S S , ZHANG J S , et al . EV-101: a phase Ⅰ study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma [J ] . J Clin Oncol , 2020 , 38 ( 10 ): 1041 - 1049 .

POWLES T , ROSENBERG J E , SONPAVDE G P , et al . Enfortumab vedotin in previously treated advanced urothelial carcinoma [J ] . N Engl J Med , 2021 , 384 ( 12 ): 1125 - 1135 . DOI: 10.1056/NEJMoa2035807 http://doi.org/10.1056/NEJMoa2035807 http://www.nejm.org/doi/10.1056/NEJMoa2035807 http://www.nejm.org/doi/10.1056/NEJMoa2035807

FAN Y , LI Q H , SHEN Q , et al . Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants [J ] . Front Oncol , 2022 , 12 : 858865.

BARDIA A , MAYER I A , DIAMOND J R , et al . Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer [J ] . J Clin Oncol , 2017 , 35 ( 19 ): 2141 - 2148 . DOI: 10.1200/JCO.2016.70.8297 http://doi.org/10.1200/JCO.2016.70.8297

FALTAS B , GOLDENBERG D M , OCEAN A J , et al . Sacituzumab govitecan, a novel antibody: drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma [J ] . Clin Genitourin Cancer , 2016 , 14 ( 1 ): e75 - e79 . DOI: 10.1016/j.clgc.2015.10.002 http://doi.org/10.1016/j.clgc.2015.10.002 https://linkinghub.elsevier.com/retrieve/pii/S155876731500258X https://linkinghub.elsevier.com/retrieve/pii/S155876731500258X

SHENG X , YAN X , WANG L , et al . Open-label, multicenter, phase Ⅱ study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma [J ] . Clin Cancer Res , 2021 , 27 ( 1 ): 43 - 51 . DOI: 10.1158/1078-0432.CCR-20-2488 http://doi.org/10.1158/1078-0432.CCR-20-2488 https://aacrjournals.org/clincancerres/article/27/1/43/83538/Open-label-Multicenter-Phase-II-Study-of-RC48-ADC https://aacrjournals.org/clincancerres/article/27/1/43/83538/Open-label-Multicenter-Phase-II-Study-of-RC48-ADC

SENG X N , HE Z S , HAN W Q , et al . An open-label, single-arm, multicenter, phase Ⅱ study of RC48 to evaluate and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009) [R ] . ASCO , 2021 : abstract 4584.

ZHOU L , XU H Y , LI S M , et al . Study RC48-C014: preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma [J ] . J Clin Oncol , 2022 , 40 ( 6_suppl ): 515 .